This PDF is the current document as it appeared on Public Inspection on 04/16/2014 at 08:45 am.
Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of the following meeting.
The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.
Name of Committee: National Institute of Allergy and Infectious Diseases Special Emphasis Panel; NIAID SBIR Phase II Clinical Trial Implementation Cooperative Agreement (U44) and Clinical Trial Planning Grants (R34).
Date: May 12, 2014.
Time: 1:00 p.m. to 5:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, 6700B Rockledge Drive, Bethesda, MD 20817, (Telephone Conference Call).
Contact Person: Quirijn Vos, Ph.D., Scientific Review Officer Scientific Review Program, Division of Extramural, Activities DHHS/NIH/NIAID, 6700B Rockledge Drive, MSC, 7616 Bethesda, MD 20892, 301-451-2666, email@example.com.
(Catalogue of Federal Domestic Assistance Program Nos. 93.855, Allergy, Immunology, and Transplantation Research; 93.856, Microbiology and Infectious Diseases Research, National Institutes of Health, HHS).Start Signature
Dated: April 11, 2014.
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2014-08680 Filed 4-16-14; 8:45 am]
BILLING CODE 4140-01-P